Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on June 14, 2021. The filing discloses the commencement of a public offering of senior notes. The company is incorporated in Delaware and maintains its principal executive offices in Nashville, Tennessee.
Key Financial Metrics and Capital Structure
The filing details a specific debt issuance event rather than reporting operational financial metrics such as revenue, profit, or cash flow.
- New Debt Issuance: $17,500,000 aggregate principal amount of 8.625% Senior Notes due 2026.
- Existing Debt: $55,000,000 aggregate principal amount of 8.625% Senior Notes due 2026 outstanding prior to this offering.
- Trading Symbol: HROWL (for the Senior Notes) on The NASDAQ Global Market.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase additional senior notes.
The filing text does not provide clear values for revenue, operating margins, liquidity ratios, or total debt beyond the specific note issuances mentioned.
Material Changes
The primary material change is the expansion of the company's debt capital structure. The new notes will be treated as a single series with the existing notes, sharing the same CUSIP number and trading interchangeably. They are expected to be fungible for U.S. federal income tax purposes.
Outlook, Risks, and Management Commentary
Management has issued forward-looking statements regarding the performance of the business, the terms of the offering, and the intended use of proceeds. The filing includes a standard cautionary note that actual results may differ materially from expectations due to risks identified in the company's Annual Report on Form 10-K for the year ended December 31, 2020, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. The company undertakes no obligation to update these forward-looking statements.
Key Facts for Investor Verification
- Verify the final closing date and total proceeds of the $17.5 million offering.
- Confirm the specific use of proceeds as detailed in the accompanying press release (Exhibit 99.1).
- Monitor whether the underwriters exercise the 30-day option to purchase additional notes.
- Review the company's most recent 10-K and 10-Q filings for comprehensive liquidity and solvency metrics not included in this 8-K.